May 9, 2013 | By Márcio Barra
Last week Apifarma (the Portuguese association of pharmaceutical industry) released their annual report on the pharmaceutical industry entitled “THE PHARMACEUTICAL INDUSTRY IN FIGURES”, concerning 2012. It’s available through here, and fortunately for international readers it’s available in both English and Portuguese, in the same document. The report is filled with some interesting European and national indicators and numbers on the pharma industry. The data on Portugal especially warrants a read, and a somewhat grim image is painted by the numbers in the report. Here are some highlights:
- The report features a handy breakdown on the prices of medicinal products and the many price legislative revisions that occurred through the years. In 2012, the new pricing methodology was adopted, with a new set of reference countries (Spain, Slovenia and Italy), new marketing margins for wholesalers and pharmacies, and new generic prices (50% below the RRP of the reference product, or 25% if the wholesale price is less than 10 €). This led to a lot of branded drugs seeing their price decrease.
- Medicines exportations, in M€, increased 40,2% in 2012 face 2011. 703 M€ were exported from Portugal in 2012, versus the 593 M€ in 2011. No wonder Infarmed is cracking down on distributers and pharmacies.
- In 2011, Infarmed granted 785 market authorizations, versus the 940 granted in 2010. The vast majority of them were through the decentralized procedure, followed by the national procedure.
- Manufacturing of raw materials and pharmaceutical products is decreasing in Portugal ever since 2008, with 2012 being the worst year thus far.
- From 2011 to 2012, generic drugs experienced a 134,2% growth in number, from 8.979 to 9.516.
- In 2011, the two most reimbursed therapeutic classes were drugs for the cardiovascular system, followed by drugs for the central nervous system. Be on the lookout for my next article on drug reimbursement in Portugal!
And many more. Again, you can find the report through here